Clinical Trial Update: IBIS: Italian Burden of Illness on Schizophrenia & Bipolar Disorder

View source ↗

Summary

The IBIS study in Italy assessing the burden of illness for schizophrenia and bipolar disorder has completed, sponsored by AstraZeneca.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Schizophrenia

Snippet

Sponsor: AstraZeneca | Conditions: Schizophrenia, Bipolar Disorder | Status: COMPLETED